From the ∗Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology, Chiba

†Integrative Brain Imaging Center

Departments of ‡Neurology

§Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.

Received for publication March 29, 2022; revision accepted July 23, 2022.

Conflicts of interest and sources of funding: This study was supported by the Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) project (grant 16dm0207017h0003), the Japan Agency for Medical Research and Development, an Intramural Research (grant 27-9) for Neurological and Psychiatric Disorders from the National Center of Neurology and Psychiatry (Japan), and JSPS KAKENHI (grants 15K09369 and 15K09981). The authors declare no conflicts of interest.

Correspondence to: Etsuko Imabayashi, PhD, MD, Diagnostic and Therapeutic Nuclear Medicine Group, Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institute for Quantum Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba, Japan 263-8555. E-mail: [email protected]